BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Policy

  Moderna/NIH Patent Dispute Over COVID-19 Vaccine Goes Public

  Public Citizen urged NIH director Dr. Francis Collins to clarify the NIH’s role in Moderna’s vaccine publicly and explain what he plans to ensure that federal scientists are credited for their work.

  November 10, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Exavir Aims CRISPR Program at HIV, Sees Powerful Preclinical Results

  Exavir Therapeutics announced that it was able to eliminate HIV from human cells with lipid nanoparticle (LNP)-delivered Tat-targeted CRISPR-Cas9.

  November 10, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Biotech Bay

  Biotech Companies are Expanding the Frontiers of Engineered Cell Therapy

  Celares and Mission Bio are part of the rapidly evolving push to create and characterize the superhuman powers cells can be endowed with.

  November 10, 2021

   · 

  6 min read

   · 

  Maggie Chen
• 

  Drug Development

  AC Immune Alzheimer’s Drug Reduces Cognitive Decline but Misses Functional Endpoints

  AC Immune’s Phase II Lauriet study of investigational anti-Tau monoclonal antibody, semorinemab, in mild-to-moderate Alzheimer’s disease (AD), only met one endpoint.

  November 10, 2021

   · 

  2 min read

   · 

  Heather McKenzie
• 

  Business

  Money on the Move: November 3 – 9

  Investors are lighting up the season already for these biotechs, now flush with cash to spend. Here’s who snagged funding this week.

  November 10, 2021

   · 

  4 min read

   · 

  Kate Goodwin
• 

  Business

  Angany Partners with Mass General on Potential Peanut Allergy Vaccine

  Angany entered into collaboration for a series of preclinical studies that will evaluate the safety and efficacy of BP/AH-01, Angany’s lead peanut allergy biological candidate.

  November 10, 2021

   · 

  3 min read

   · 

  Kaylei Whalen
• 

  FDA

  COVID-19 Update: Pfizer Requests Broad Booster Authorization, Long COVID Questioned

  Pfizer and BioNTech requested the FDA authorize booster shots for their COVID-19 vaccine for all adults 18 years and older, presenting data not available in September.

  November 10, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Biogen Investigates Death of 75-Year-Old on Aduhelm

  The company is investigating the death of a 75-year-old woman who died of ARIA while receiving Aduhelm.

  November 10, 2021

   · 

  4 min read

   · 

  Mark Terry
• 

  Business

  Poseida Goes All-In on Allogeneic CAR-T; Ligand Explores Spin-Off

  Eric Ostertag, CEO of Poseida Therapeutics, believes the future of CAR-T programs is with allogeneic approaches and not autologous.

  November 10, 2021

   · 

  4 min read

   · 

  Alex Keown
• 

  Policy

  Weighing the Risks and Benefits of the COVID-19 Vaccine for Kids

  Between January 4, 2020 and October 30, 2021, COVID-19 accounted for 576 deaths among children 17 and younger, compared to 189 from influenza, according to the CDC.

  November 10, 2021

   · 

  6 min read

   · 

  Gail Dutton